Journal of Clinical Medicine (Dec 2023)

Preparing Enteral Formulas for Adult Patients with Phenylketonuria: A Minor Necessity but Major Challenge—A Case Report

  • Adriana Pané,
  • Marcos Carrasco-Serrano,
  • Camila Milad,
  • Pere Leyes,
  • Pedro Juan Moreno-Lozano,
  • Roser Ventura,
  • José Cesar Milisenda,
  • Francesc Josep García-García,
  • Glòria Garrabou,
  • Judit García-Villoria,
  • Rosa Maria López-Galera,
  • Antonia Ribes,
  • Josep Maria Grau-Junyent,
  • Maria de Talló Forga-Visa,
  • Cristina Montserrat-Carbonell,
  • on behalf of PKU.CAT Consortium

DOI
https://doi.org/10.3390/jcm12237452
Journal volume & issue
Vol. 12, no. 23
p. 7452

Abstract

Read online

Phenylketonuria (PKU) is the most frequent of the congenital errors of amino acid (AA) metabolism worldwide. It leads to the accumulation of the essential AA phenylalanine (Phe) and it is associated with severe neurological defects. The early diagnosis and treatment of this rare disease, achieved through newborn screening and low-Phe diet, has profoundly changed its clinical spectrum, resulting in normal cognitive development. We face the first generation of PKU patients perinatally diagnosed and treated who have reached adulthood, whose special needs must be addressed, including feeding through enteral nutrition (EN). However, recommendations regarding EN in PKU constitute a gap in the literature. Although protein substitutes for patients with PKU are offered in multiple forms (Phe-free L-amino acid or casein glycomacropeptide supplements), none of these commercial formulas ensures the whole provision of daily total energy and protein requirements, including a safe amount of Phe. Consequently, the combination of different products becomes necessary when artificial nutrition via tube feeding is required. Importantly, the composition of these specific formulas may result in physicochemical interactions when they are mixed with standard EN products, leading to enteral feeding tubes clogging, and also gastrointestinal concerns due to hyperosmolality. Herein, we present the first reported case of EN use in an adult patient with PKU, where the separate administration of protein substitutes and the other EN products avoided physicochemical interactions.

Keywords